Holen Sie sich die Stockscreener-App
14.21
0.11%
-0.015
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$14.23
Offen:
$14.45
24-Stunden-Volumen:
11.93M
Relative Volume:
0.68
Marktkapitalisierung:
$6.44B
Einnahmen:
$285.55M
Nettoeinkommen (Verlust:
$-353.86M
KGV:
-14.96
EPS:
-0.9501
Netto-Cashflow:
$-305.02M
1W Leistung:
+29.23%
1M Leistung:
+64.91%
6M Leistung:
+314.43%
1J Leistung:
+531.78%
1-Tages-Spanne:
$13.95
$14.75
1-Wochen-Bereich:
$10.68
$15.30
52-Wochen-Spanne:
$1.76
$15.30
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
14.21 | 4.98B | 285.55M | -353.86M | -305.02M | -0.9501 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Hochstufung | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
What’s Behind Iovance Biotherapeutics (IOVA) Latest Move? - Simply Wall Street
Iovance appoints Noah Berkowitz as chief medical officer - Investing.com
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., As Chief Medical Officer - TradingView
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
Iovance Biotherapeutics Is Maintained at Overweight by Wells Fargo - Moomoo
IOVA Stock Soars As Revenue Outlook Jumps And Analysts Chase - StocksToTrade
IOVA Stock Surges As Revenue Guidance Reset Triggers Bull Run - timothysykes.com
IOVA Maintains Rating by Wells Fargo -- Price Target Raised to $18 - GuruFocus
Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On? - Benzinga
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 - TradingView
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains? - Yahoo Finance
Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth -- Barrons.com - Moomoo
Fair Issac Corp., Iovance Biotherapeutics, Stablecoin Development Corp., Carnival Corp. and Micron: Why T - Benzinga
Iovance Biotherapeutics (IOVA) Eyes 60% Revenue Growth, Shares Jump 31% - Yahoo Finance
Cash flow from financing activities of Iovance Biotherapeutics Inc – HAN:2LB - TradingView
Iovance: The Turnaround Is Priced In, Downgrading To Hold (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics raises 2026 revenue for... - Pluang
Iovance Biotherapeutics (IOVA) Shares Surge Over 30% After Raisi - GuruFocus
Update: Iovance Biotherapeutics Shares Jump After 2026 Revenue Guidance Raised - Yahoo Finance
Iovance stock rises as analysts cheer new outlook (IOVA:NASDAQ) - Seeking Alpha
Iovance Lifts 2026 Revenue Outlook by $55 Million on Amtagvi Demand, Shares Hit Two-Year High - finance.biggo.com
Iovance Biotherapeutics, Inc. stock Analysis: 2026 Rally Meets Overbought Alerts - The Cryptonomist
Iovance Biotherapeutics Surges After Lifting 2026 Revenue Outlook - Moomoo
Iovance Raises 2026 Revenue Guidance on Strong Demand - grafa.com
Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars - TradingView
Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth - Barron's
IOVA Maintained by HC Wainwright & Co. -- Price Target Raised to $20 - GuruFocus
HC Wainwright & Co. maintains Buy rating on Iovance Biotherapeutics, $20 price target - TradingView
CarMax Posts Upbeat Q2 Earnings, Joins Iovance Biotherapeutics, Perella Weinberg Partners And Other Big S - Benzinga
IOVA Stock Hits Over 2-Year Highs – Why Iovance Raised Its FY2026 Revenue Outlook - Yahoo Finance
Iovance Raises 2026 Revenue Guidance to $410 Million-$420 Million - Yahoo Finance
Iovance Biotherapeutics Stock Draws Bullish Targets As Amtagvi Launch Turns - timothysykes.com
IOVA Stock Draws Bullish Targets As Amtagvi Momentum Builds - StocksToTrade
Iovance shares jump in premarket as raised outlook clears consensus views - Investing.com
Form 8K Iovance Biotherapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Why is Iovance Biotherapeutics stock surging today? By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics (IOVA) Raises 2026 Revenue Forecast Above Analyst Estimates - GuruFocus
Iovance raises 2026 revenue guidance to $410-420 million - Investing.com
Iovance Biotherapeutics Raises 2026 Revenue Guidance Outlook - TipRanks
Iovance Biotherapeutics Raises 2026 Revenue Guidance - marketscreener.com
Nearly 60% revenue growth is implied by Iovance's 2026 forecast. - Stock Titan
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million - Yahoo Finance
How (IOVA) Movements Inform Risk Allocation Models - Stock Traders Daily
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Iovance Biotherapeutics, Inc. (IOVA) Options Chain - Yahoo! Finance Canada
IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Stocktwits
Iovance Biotherapeutics stock hits 52-week high at 10.98 USD - Investing.com
Iovance Biotherapeutics stock hits 52-week high at 10.98 USD By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics Price Target Announced at $15.00/Share by Goldman Sachs - moomoo.com
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
IOVA Stock Price, Quote & Chart - ChartMill
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Iovance Biotherapeutics Inc-Aktie (IOVA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BILINSKY IGOR | Chief Operating Officer |
Sep 08 '26 |
Option Exercise |
0.00 |
7,813 |
0 |
146,050 |
| Puri Raj K. | Chief Regulatory Officer |
Sep 08 '26 |
Option Exercise |
0.00 |
9,766 |
0 |
260,842 |
| Vogt Frederick G | Interim CEO & General Counsel |
Sep 01 '26 |
Option Exercise |
0.00 |
41,669 |
0 |
604,161 |
| Puri Raj K. | Chief Regulatory Officer |
Sep 01 '26 |
Option Exercise |
0.00 |
5,470 |
0 |
253,584 |
| BILINSKY IGOR | Chief Operating Officer |
Sep 01 '26 |
Option Exercise |
0.00 |
8,789 |
0 |
142,709 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Aug 10 '26 |
Option Exercise |
0.00 |
10,001 |
0 |
156,947 |
| Roche Corleen M. | Chief Financial Officer |
Aug 06 '26 |
Option Exercise |
0.00 |
49,995 |
0 |
49,995 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 05 '26 |
Option Exercise |
0.00 |
15,625 |
0 |
569,130 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
7,813 |
0 |
144,087 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
9,766 |
0 |
251,957 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):